KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Receivables (2018 - 2026)

Twist Bioscience has reported Receivables over the past 9 years, most recently at $64.3 million for Q1 2026.

  • Quarterly Receivables rose 24.97% to $64.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $64.3 million through Mar 2026, up 24.97% year-over-year, with the annual reading at $57.3 million for FY2025, 55.17% up from the prior year.
  • Receivables was $64.3 million for Q1 2026 at Twist Bioscience, up from $62.4 million in the prior quarter.
  • Over five years, Receivables peaked at $64.3 million in Q1 2026 and troughed at $34.6 million in Q2 2024.
  • The 5-year median for Receivables is $46.0 million (2022), against an average of $46.8 million.
  • Year-over-year, Receivables soared 2084.7% in 2022 and then fell 25.71% in 2024.
  • A 5-year view of Receivables shows it stood at $44.6 million in 2022, then decreased by 15.2% to $37.9 million in 2023, then grew by 8.71% to $41.2 million in 2024, then soared by 51.54% to $62.4 million in 2025, then grew by 3.05% to $64.3 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Receivables are $64.3 million (Q1 2026), $62.4 million (Q4 2025), and $57.3 million (Q3 2025).